Cereno Scientific AB is a research and development company, which engages in the discovery and development of drug for the preventive treatment of thrombosis related diseases. Its product pipeline include CS1, a reformulation of valproic acid that restores the body's balance between the systems and decreases the risk of blood clot in myocardial infarction or stroke. The company was founded by Claes Sverker Jern, Niklas Olof Bergh, and Pia Larsson in April 2012 and is headquartered in Molndal, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company